Biosimilars: British Columbia extends transition program

By Aurélia Morvan | Oct. 3, 2019, 11:14 a.m.

Photo: Freepik

Rising drug costs are plaguing public and private health insurance plans alike. In response to this trend, British Columbia has extended its program which transitions patients to biosimilar drugs.

This article is reserved to PRO Level subscribers

Discover the PRO Level
Related topics …